# Special Issue

# Novel Biomarkers and Diagnostic Methods of Cardiovascular Disease

# Message from the Guest Editors

The understanding of cardiovascular diseases and their management has changed dramatically over the last 30 years with the identification of various pathways and the successful development of effective therapies that target them. This has led to a concomitant reduction in mortality and morbidity and an improvement in the functional capacity and quality of life of these patients. However, there are still major unmet needs in the management of these diseases; they continue to be the number one cause of death globally with the social and economic impact remaining largely unchanged. Therefore, it is of utmost importance to identify novel biomarkers and diagnostic methods through endeavors in basic research areas to better understand the disease mechanisms, identify novel biomarkers for early intervention, improved diagnosis, and experimental medicine for better disease management. This Special Issue in the Journal of Personalized Medicine will encompass both review and original research articles by experts in the field.

### **Guest Editors**

Dr. Estefanía Tarazón

1. Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain 2. Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Madrid, Spain

Dr. Esther Rosello-Lleti

Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain

## Deadline for manuscript submissions

closed (10 December 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/102580

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

## **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

